Cryospray ablation (CSA) in the palliative treatment of squamous cell carcinoma of the esophagus.

Primary tabs

field_vote: 
Average: 7 (1 vote)
Number of included patients: 
Publication type: 
Therapeutic intervention: 

World J Surg Oncol. 2007 Mar 16;5:34.
Cryospray ablation (CSA) in the palliative treatment of squamous cell carcinoma of the esophagus.
 
Cash BD, Johnston LR, Johnston MH.
Department
of Gastroenterology, National Naval Medical Center, Bethesda, MD 8901
Wisconsin Avenue, Bldg 9, Department of Gastroenterology, Bethesda, MD
20889, USA.

BACKGROUND:
Esophageal carcinoma is the ninth most prevalent cancer worldwide with
squamous cell carcinoma (SCCA) and adenocarcinoma accounting for the
vast majority of new cases (13,900 in 2003). Cure rates in the U.S. are
less than 10%, similar to lung cancer. More than 50% of patients with
esophageal carcinoma present with unresectable or metastatic disease,
are not surgical candidates, or display disease progression despite the
addition of neoadjuvant chemoradiotherapy to surgery. Need for improved
palliation exits.
CASE PRESENTATION: This case describes a 73-year-old
African American male who presented with recurrent squamous cell
carcinoma (SCCA) of the esophagus who has a achieved complete remission
for 24 months via endoscopic cryospray ablation.
CONCLUSION: Endoscopic
cryo spray ablation warrants further investigation as a palliative
treatment modality for esophageal cancer. This is the first reported
case in the medical literature.